Subjects with abdominal obesity are characterized by hyperactivity of the hypothalamic ± pituitary ± adrenal (HPA) axis, which leads to a condition of`functional hypercortisolism'. This appears to be the result of two distinct mechanisms. The ®rst, which appears to be central in origin, is characterized by altered ACTH pulsatile secretory dynamics and by hyper-responsiveness of the HPA axis to different neuropeptides and acute or chronic stress events and, possibly, to selected dietary factors. The other appears to be located in the periphery, speci®cally the liver and visceral adipose tissue, and is characterized by supranormal cortisol production, whose paracrine and systemic effects remain unclear. It is suggested that increased exposure to cortisol of the body may play a fundamental role not only in the development of increased fat in abdominalavisceral depots, but also in determining all metabolic abnormalities closely related to the abdominal obesity phenotype.
Introduction
There is emerging evidence that the activity of the hypothalamic ± pituitary ± adrenal (HPA) axis is dysregulated in many obese individuals, particularly those in whom the abdominal or visceral phenotype leads to a condition that could be de®ned as`functional hypercortisolism'. 1 In fact, abdominal obesity is often characterized by several Cushing-like features, including all abnormalities of the so-called metabolic syndrome. In patients with Cushing's syndrome, the main metabolic abnormality of cortisol excess is represented by insulin resistance, which develops by cellular mechanisms that have been largely elucidated. Brie¯y, glucocorticoids inhibit glucose uptake by peripheral tissues, stimulate gluconeogenesis, and cause an increase in post-absorptive glucose and insulin. In the insulin sensitive tissues, glucocorticoids also impair the post-receptor insulin function by mechanisms that involve interaction with glucose transporters. Treatment of hypercortisolism by pituitary or adrenal surgical procedures can completely reverse these abnormalities. It has been hypothesized that, similarly to what occurs in Cushing's syndrome, functional hypercorticism', which characterizes abdominal obesity, may have an important role in determining the insulin resistant state and related metabolic alterations. In addition, cortisol excess may have a key role in the development of enlarged abdominal or visceral fat. This is probably favoured by the synergistic effect of prevailing hyperinsulinemia and by reduced growth hormone and decreased (in male obesity) or increased (in female obesity) free androgen availability in peripheral tissues. 1 The dysregulation of the HPA axis in abdominal obesity appears to be the result of two distinct alterations. The ®rst, which appears to be central in origin, is characterized by altered ACTH pulsatile secretory dynamics and by hyper-responsiveness of the HPA axis to different neuropeptides and acute or chronic stress events and, possibly, to selected dietary factors. The other appears to be located in the periphery, speci®cally the liver and visceral adipose tissue, and is characterized by supranormal cortisol production, whose paracrine and systemic effects remain to be elucidated. Table 1 summarizes all abnormalities still demonstrated in obese subjects most of which will be discussed in the following paragraphs.
Evidence for a neuroendocrine alteration of the HPA axis in abdominal obesity Serum basal concentrations of ACTH and cortisol are usually normal in visceral obesity, although slightly lower morning cortisol levels have been reported by some authors. 2 Pulsatility studies have recently shown that women with visceral obesity had higher ACTH pulse frequency and lower ACTH pulse amplitude, despite similar mean ACTH basal concentrations, in comparison with women with peripheral type obesity and normal weight controls. 3 Interestingly, the alterations of pulsatile parameters were evident only in the morning, and differences between the groups disappeared during both early and late afternoon. On the other hand ACTH abnormalities were not accompanied by alterations of either cortisol mean blood levels or pulsatile parameters. Signi®cant alterations in the correlations between ACTH and adrenal glucocorticoids, which have been repeatedly reported under different experimental conditions in both experimental animals and humans, may be related to a complex metabolism of cortisol and to the fact that it can be produced also in extra-adrenal tissues. In the few studies in which corticotropin-releasing hormone (CRH) concentrations were measured in the cerebrospinal¯uid, normal or decreased values have been reported. The interpretation of these ®ndings is dif®cult, but preliminary data are consistent with the hypothesis that leptin, the product of the ob gene secreted in the adipose tissue, may exert an inhibiting action upon both CRH and ACTH secretion at the hypothalamic level. 4 Daily pulsatile activity of the HPA axis is disrupted by meals after which, particularly at noon, a sustained cortisol surge occurs, which is independent of the circadian rhythm and pulsatile dynamics. Recent studies performed by Korbonits et al 5 and our group 3 indicate that the activation of the HPA following a mixed meal may be signi®cantly higher in women with abdominal obesity than in those with the peripheral phenotypes or in normal weight controls. We obtained the same results after carbohydrate-rich or proteinalipid-rich meals (unpublished data). These ®ndings suggest that subjects with abdominal obesity are inappropriately exposed to supranormal cortisol levels which, in turn, may have a negative impact on the regulation of postprandial fuel metabolism and on insulin action in peripheral tissues.
Dynamic studies in which the HPA axis was either stimulated or inhibited had provided the most convincing evidence for a dysregulation of the system in abdominal obesity. Examples of such a dysregulation are: high secretion of cortisol after a laboratory stress test; elevated ACTH and cortisol secretion after administration of CRF alone or combined with arginine-vasopressin (AVP); elevated cortisol concentrations following challenges with maximal or low-dose ACTH; and reduced cortisol suppression after low dose midnight dexamethasone administration. 6 Taken together, this might mean sensitized andaor hyperresponsive hypothalamic centers, pituitary as well as adrenal regulatory mechanisms, that result in slightly but inappropriately elevated net cortisol production, either continuous or episodic, in individuals with abdominal obesity.
Mechanisms responsible for the alterations of the HPA axis activity at the central levels are completely unknown. We recently hypothesized that one of these factors may be related to abnormal catecholaminergic regulation of the HPA axis activation. In fact catecholamines are important modulators of CRH and ACTH secretion, particularly during acute and chronic stress challenges. These effects are predominantly mediated by a1 and a2 adrenoreceptor subtype. In particular, a2-adrenoreceptors mediate inhibiting effects on ACTH release in experimental animals and in humans, and it has been suggested that this provides a negative feedback mechanism that prevents excessive glucocorticoid response to internal and external stressor stimuli. After i.v. administration of yoimbine, an a2-adrenoreceptor antagonist, in order to achieve steady-state norepinephrine plasma levels near to those observed during acute stress, we found that ACTH response to combined CRH AVP challenge was slightly but signi®cantly reduced in normal weight controls, in comparison with that observed during the control test, whereas in the obese women, particularly the abdominal phenotype, the response of ACTH was signi®cantly increased. 7 These disparate effects after a2-adrenoreceptor inhibition between normal weight controls and abdominally obese women indicate different sensitivity to central noradrenergic tone of the HPA axis activity, thus suggest that obese women with abdominal body fat distribution may escape physiological a2-adrenoreceptor control, thus favouring inappropriate HPA axis excitation Evidence for a peripheral alteration of the HPA axis in abdominal obesity
Cortisol is metabolized in the liver and adipose tissue by A-ring reductase, but additional metabolism occurs by 11b-hydroxysteroid dehydrogenase (11bHSD) in the kidney. However, the metabolic clearance rate of cortisol is in¯uenced by its regeneration from inactive cortisone in the liver, fat, and skeletal muscle by 11b-reductase. 8 The whole body equilibrium between cortisol and cortisone, its inactive form, is determined by the balance of tissue-speci®c activities of 11b-dehydrogenase (the product of the 11b-hydroxysteroid deydrogenase type 2 gene, 11bHSD 2 ) and 11b-reductase (the product of the 11b-hydroxysteroid deydrogenase type 1, 11bHSD 1 ). The expression of the 11bHSD 2 , which inactivates cortisol to cortisone in the kidney and other mineralcorticoid target tissues, thereby protecting mineralcorticoid receptors from inappropriate activation by cortisol, is not related to obesity. Consistent with animal studies, 11BHSD 2 appears to be a constitutive enzyme which is not hormonally regulated. However, 11bHSD 1 is downregulated by insulin and estrogens and appears to be dysregulated in obesity. Recently, Bujalska et al 9 found that the production of cortisol from cortisone (and therefore the activity of the 11bHSD 1 ) in the omental fat tissue taken from normal weight and obese patients undergoing surgical procedures was signi®cantly higher than in the subcutaneous fat, the activity of the enzyme being further increased by tissue exposure to cortisol and insulin. More recently, Andrew et al 10 measured cortisol and cortisone and their metabolites by gas chromatographyamass spectrometry in a non-selected group of obese subjects of both sexes and found that the ratio between tetrahydrocortisol and tetrahydrocortisone derivatives, which can be assumed as an index of 11bHSD 1 activity, was higher in obese men and women than in nonobese controls and was signi®cantly and positively correlated with abdominal circumference, thus suggesting an increased conversion of cortisone to cortisol in obesity, particularly in the abdominal phenotype.
The function of the increased availability of cortisone in peripheral tissues, particularly fat tissue, is presently unknown. Theoretically, the inappropriate constant exposure of glucocorticoids to fat, particularly visceral fat, may play a potential role in determining differentiation and mass increase of such a tissue. In addition, it may represent an inappropriate feedback signal at the neuroendocrine levels, and be able to modify both basal activity of the HPA axis and its response to stimulatory andaor inhibitory factors.
